Skip to content
Screener

ArriVent BioPharma, Inc. AVBP Q1 2026 earnings

Reported May 11, 2026 · Before market open

EPS-$0.96Miss by $0.08
EPS estimate-$0.88

Next report

Nov 16, 2026 (in 2 months)
Revenue estimate$800.0K
EPS estimate-$1.07

Financials

Q1 2026

Income statement

See full
Operating income-$46.1M+30.9%
Net income-$43.3M+32.7%
EPS (diluted)-$0.96+49.5%

Balance sheet

See full
Cash & equivalents$62.1M+24.5%
Total debt$419.0K+204%
Total equity$324.0M+60.0%
Total assets$349.3M+62.1%

Cash flow

See full
Operating cash flow-$41.9M+38.4%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$1.02B+62.1%
Enterprise value$958.05M+65.4%

Returns & leverage

See full
Return on equity-55.2%+8.0pp
Debt / equity0×0.0×
Current ratio14×-0.4×

FAQ

When did ArriVent BioPharma, Inc. report Q1 2026 earnings?
ArriVent BioPharma, Inc. (AVBP) reported Q1 2026 earnings on May 11, 2026 before market open.
What were ArriVent BioPharma, Inc.'s Q1 2026 revenue and EPS?
ArriVent BioPharma, Inc. reported eps of $-0.96 for Q1 2026.
Did ArriVent BioPharma, Inc. beat estimates in Q1 2026?
EPS missed the consensus estimate of $-0.88 by $0.08.
How did ArriVent BioPharma, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 49.5% from $-1.90.
Where can I find ArriVent BioPharma, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001104659-26-058638) and the 10-Q periodic report (0001104659-26-058650) directly on SEC EDGAR. The filing index links above go to sec.gov.